Nano-X and BCAL Diagnostics win 1776 Regional Final
Nano-X offers a new radiotherapy machine with disruptive market advantages. By moving the complexity of a radiotherapy system from hardware to software, Nano-X is less expensive to produce, less expensive to site, requires fewer staff to operate and can deliver a more complete therapy to patients.
BCAL Diagnostics, a graduate of the 2015 MDCTP program, delivered by ATP Innovation, aims to shift the paradigm in breast cancer screening and diagnosis by introducing a blood test for detection of the disease. The implication of such a technology could revolutionise detection and management of breast cancer by allowing a blood sample to be taken remote from the site of analysis.